Table 1

Preclinical studies of neoadjuvant oncolytic virotherapy

Authors	Title	Model	Virus	Reference
Jarnagin, et al33	Neoadjuvant treatment of hepatic malignancy: an oncolytic HSV expressing IL-12 effectively treats the parent tumor and protects against recurrence-after resection	Hepatic	NV1042 and NV1023 HSV	26
Tai et al34	Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells	Lymphoma, melanoma, TNBC	ORFV	27
Bourgeois-Daigneault et al35	Neoadjuvant oncolytic virotherapy before surgery sensitizes TNBC to immune checkpoint therapy	TNBC	Maraba	28
Ahmed et al25	A new oncolytic VV augments antitumor immune responses to prevent tumor recurrence and metastasis after surgery	Colon, rectal, LLC, OSCC, pancreatic	VVΔTKΔN1L and VVΔTKΔN1L-IL12	30
Yamada et al26	Neoadjuvant use of oncolytic HSV G47Δ; enhances the antitumor efficacy of radiofrequency ablation	Neuroblastoma	G47Δ HSV	32
Niavarani et al53	Oncolytic VSV-based cellular vaccine improves TNBC outcome by enhancing natural killer and CD8+ T-cell functionality	TNBC	VSVd51	47
Martin et al54	Presurgical neoadjuvant oncolytic virotherapy confers protection against rechallenge in a murine model of breast cancer	TNBC	VSV, adenovirus, reovirus and HSV	48

HSV, herpes simplex virus; IL-12, interleukin 12; LLC, Lewis lung carcinoma; ORFV, parapoxvirus ovis; OSCC, oral squamous cell carcinoma; TNBC, triple-negative breast cancer; VSV, vesicular stomatitis virus; VV, vaccinia virus.